Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding awards under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing details a change in the interests of a connected person of an Executive Director:
- Director: Dr M Slaoui (Executive Director)
- Connected Person: Dr K Slaoui
- Transaction: Award of 2,030 American Depositary Shares (ADSs) under the 2009 Performance Share Plan.
- Date of Award: February 11, 2016
- Market Price: The closing price of an ADS on February 11, 2016, was $39.15.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a director-related transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the total number of ADSs awarded to Dr K Slaoui (2,030) and the associated valuation based on the $39.15 closing price.
- Confirm the terms of the GlaxoSmithKline 2009 Performance Share Plan to understand vesting conditions attached to these awards.
- Review subsequent filings to determine if this transaction impacts the overall executive compensation structure or insider ownership percentages.